Health
MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials – News-Medical.Net
A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic….
The modified vaccina virus Ankara (MVA) is an attenuated vaccinia virus that has been used as a vector in the already approved Adenovirus-MVA-based Ebola vaccine. A new preprint appearing on the bioRxiv* server reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that is causing the current coronavirus disease 2019 (COVID-19) pandemic. The MVA provides a vector platform for the rapid production…
-
Business24 hours agoWhich ASX shares are ahead of the pack in mitigating US tariffs?
-
General20 hours agoAntoinette Lattouf’s lawyers push for $350k penalty over ABC’s contraventions of Fair Work Act
-
Noosa News20 hours agoJudge draws on brother’s care – Proctor
-
Business20 hours agoAustralia’s highest earners are betting big on these ASX ETFs